MX2022005509A - Compuestos inhibidores de rip1 heterociclicos. - Google Patents
Compuestos inhibidores de rip1 heterociclicos.Info
- Publication number
- MX2022005509A MX2022005509A MX2022005509A MX2022005509A MX2022005509A MX 2022005509 A MX2022005509 A MX 2022005509A MX 2022005509 A MX2022005509 A MX 2022005509A MX 2022005509 A MX2022005509 A MX 2022005509A MX 2022005509 A MX2022005509 A MX 2022005509A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- rip1
- inhibitory compounds
- heterocyclic
- kinase
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 title 1
- 101150040948 RIP1 gene Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 3
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente se describen compuestos inhibidores de quinasa, tales como compuestos inhibidores de proteína quinasa 1 que interactúa con el receptor (RIP1), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos pueden tener una estructura de acuerdo con la Fórmula (ver Fórmula) Fórmula I. Los compuestos, composiciones farmacéuticas y/o combinaciones descritos pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afección asociada a RIP1.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962932404P | 2019-11-07 | 2019-11-07 | |
US202063001016P | 2020-03-27 | 2020-03-27 | |
US202063004301P | 2020-04-02 | 2020-04-02 | |
US202063004319P | 2020-04-02 | 2020-04-02 | |
US202063004290P | 2020-04-02 | 2020-04-02 | |
PCT/US2020/059348 WO2021092336A1 (en) | 2019-11-07 | 2020-11-06 | Heterocyclic rip1 inhibitory compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022005509A true MX2022005509A (es) | 2022-10-18 |
Family
ID=73646543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005509A MX2022005509A (es) | 2019-11-07 | 2020-11-06 | Compuestos inhibidores de rip1 heterociclicos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11578078B2 (es) |
EP (1) | EP4055021A1 (es) |
JP (1) | JP7395730B2 (es) |
KR (1) | KR20220079919A (es) |
CN (1) | CN115298184A (es) |
AU (1) | AU2020378407B2 (es) |
CA (1) | CA3156594A1 (es) |
IL (1) | IL292536A (es) |
MX (1) | MX2022005509A (es) |
TW (1) | TW202132307A (es) |
WO (1) | WO2021092336A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
WO2022242639A1 (zh) * | 2021-05-19 | 2022-11-24 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
CN114736197B (zh) * | 2022-06-13 | 2022-09-13 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
ATE107176T1 (de) | 1989-12-04 | 1994-07-15 | Searle & Co | System zur transdermalen albuterol applikation. |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
JP5645663B2 (ja) | 2007-08-15 | 2014-12-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ネクロトーシスのヘテロ環式抑制剤 |
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
CN106573006A (zh) * | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
US10287280B2 (en) | 2015-02-13 | 2019-05-14 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide |
AU2016287581B2 (en) | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
DK3362449T3 (da) | 2015-10-13 | 2021-07-19 | Inst Nat Sante Rech Med | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
WO2017069279A1 (ja) | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
WO2017136727A2 (en) * | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
BR112019017738A2 (pt) | 2017-02-27 | 2020-04-07 | Glaxosmithkline Ip Dev Ltd | combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto |
DK3788044T3 (da) | 2018-05-03 | 2023-10-02 | Rigel Pharmaceuticals Inc | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf |
FI3788045T3 (fi) * | 2018-05-03 | 2023-06-28 | Rigel Pharmaceuticals Inc | RIP1-inhibitorisia yhdisteitä ja samojen valmistus- ja käyttömenetelmiä |
JP2022511213A (ja) | 2018-06-26 | 2022-01-31 | シャンハイ インスティテュート オブ オーガニック ケミストリー,チャイニーズ アカデミー オブ サイエンシズ | 細胞壊死阻害剤、その調製方法およびその使用 |
CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
KR20220042431A (ko) * | 2019-09-06 | 2022-04-05 | 리겔 파마슈티칼스, 인크. | 헤테로시클릭 rip1 키나제 억제제 |
-
2020
- 2020-11-06 CN CN202080092168.3A patent/CN115298184A/zh active Pending
- 2020-11-06 IL IL292536A patent/IL292536A/en unknown
- 2020-11-06 US US17/091,270 patent/US11578078B2/en active Active
- 2020-11-06 AU AU2020378407A patent/AU2020378407B2/en active Active
- 2020-11-06 EP EP20816790.8A patent/EP4055021A1/en active Pending
- 2020-11-06 JP JP2022526157A patent/JP7395730B2/ja active Active
- 2020-11-06 KR KR1020227015301A patent/KR20220079919A/ko active Search and Examination
- 2020-11-06 TW TW109138824A patent/TW202132307A/zh unknown
- 2020-11-06 CA CA3156594A patent/CA3156594A1/en active Pending
- 2020-11-06 MX MX2022005509A patent/MX2022005509A/es unknown
- 2020-11-06 WO PCT/US2020/059348 patent/WO2021092336A1/en active Application Filing
-
2022
- 2022-12-16 US US18/067,384 patent/US20230143161A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11578078B2 (en) | 2023-02-14 |
JP2023501399A (ja) | 2023-01-18 |
EP4055021A1 (en) | 2022-09-14 |
IL292536A (en) | 2022-06-01 |
AU2020378407A1 (en) | 2022-06-02 |
CN115298184A (zh) | 2022-11-04 |
AU2020378407B2 (en) | 2024-02-01 |
CA3156594A1 (en) | 2021-05-14 |
US20230143161A1 (en) | 2023-05-11 |
WO2021092336A1 (en) | 2021-05-14 |
US20210139494A1 (en) | 2021-05-13 |
KR20220079919A (ko) | 2022-06-14 |
JP7395730B2 (ja) | 2023-12-11 |
TW202132307A (zh) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002719A (es) | Inhibidores heterociclicos de la quinasa rip1. | |
PH12020551847A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
PH12020551848A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
JOP20220246A1 (ar) | مثبطات rip1k | |
CR20220075A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
SA520412335B1 (ar) | مشتقات أوكسي فلورو ببريدين كمثبط كيناز | |
ECSP22097749A (es) | Inhibidores de ripk1 | |
MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
MX2023010624A (es) | Inhibidores heterociclicos de la cinasa rip1. | |
AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 |